Fast itch relief and comparable skin clearance at week 4 - a nonsteroidal option to note for mild-moderate AD In a phase 2, dose‑ranging trial, twice‑daily 1.5% ruxolitinib cream matched…
Read More
A simple 1% colloidal oatmeal regimen cut itch and improved eczema scores within days in toddlers A small open‑label study in children aged 3-72 months tested a twice‑daily 1% colloidal…
Read More
When One Target Isn’t Enough — Dual Therapy Clears Refractory ADW An adolescent with persistent, widespread atopic dermatitis failed topical therapy and dupilumab, then achieved only partial control on upadacitinib…
Read More
Dupilumab in Diverse Skin — Are Adverse Events Really the Same? Atopic dermatitis isn’t one-size-fits-all: chronic type 2 inflammation, barrier dysfunction, and S. aureus colonization are core features, but presentation…
Read More
Healio profiled a July Journal of Drugs in Dermatology study on the affordability of dermatologist-recommended skincare products for atopic dermatitis. The study, “Socioeconomic Disparities in Gentle Skin Care Access for…
Read More
Test Your Knowledge! Join Dr. Alexis Carrington, Chief Dermatology Resident at George Washington University, to help understand dermatologic conditions across all skin tones. Decoding Derm: What’s the Diagnosis is a…
Read More
Switching from Dupilumab to Upadacitinib: Practice-Informing Evidence from LEVEL UP SWITCH This exclusive video interview with Dr. Christopher Bunick unveils the practice-changing insights of the LEVEL UP SWITCH study, designed…
Read More
Zabalafin’s All-In-One Assault On Inflammation, Infection, Dryness, and Itch Atopic dermatitis has long been driven by a vicious circle—staph overgrowth, immune flare-ups, parched skin, and relentless itch that feed one…
Read More
Catch Up on the Latest Think about the last time you saw real-world data reshape your treatment approach—what if you discovered that one of our most trusted biologics behaves differently…
Read More
From the Vault: The Heterogeneity of Atopic Dermatitis Atopic dermatitis (AD) isn’t a single-symptom disease, and treating it like one may shortchange your patients. A focused review in a JDD…
Read More
Access Inequity in Atopic Dermatitis Care: Are Your Patients Getting Left Behind? Gentle skin care is a foundation of atopic dermatitis (AD) treatment, but what happens when patients can’t afford,…
Read More
Could an Eczema Treatment Also Protect the Heart? Looking at Upadacitinib and Cardiovascular Risk Atopic dermatitis (AD) may start on the skin, but its impact goes much deeper. As a…
Read More
